152 related articles for article (PubMed ID: 38575404)
41. Octreotide-Resistant Acromegaly: Challenges and Solutions.
Corica G; Ceraudo M; Campana C; Nista F; Cocchiara F; Boschetti M; Zona G; Criminelli D; Ferone D; Gatto F
Ther Clin Risk Manag; 2020; 16():379-391. PubMed ID: 32440136
[TBL] [Abstract][Full Text] [Related]
42. Pegvisomant and not somatostatin receptor ligands (SRLs) is first-line medical therapy for acromegaly.
van der Lely AJ; Kuhn E; Muhammad A; Coopmans EC; Neggers SJ; Chanson P
Eur J Endocrinol; 2020 Jun; 182(6):D17-D29. PubMed ID: 32234975
[TBL] [Abstract][Full Text] [Related]
43. Treatment of acromegaly with the nonpeptide, highly selective somatostatin receptor type 2 agonist paltusotine.
Wildemberg LE; Fialho C; Gadelha MR
Best Pract Res Clin Endocrinol Metab; 2024 May; ():101906. PubMed ID: 38845246
[TBL] [Abstract][Full Text] [Related]
44. Novel Somatostatin Receptor Ligands Therapies for Acromegaly.
Paragliola RM; Salvatori R
Front Endocrinol (Lausanne); 2018; 9():78. PubMed ID: 29563895
[TBL] [Abstract][Full Text] [Related]
45. Oral Octreotide: A Review of Recent Clinical Trials and Practical Recommendations for Its Use in the Treatment of Patients With Acromegaly.
Yuen KCJ; Samson SL
Endocr Pract; 2022 Jun; 28(6):637-645. PubMed ID: 35452815
[TBL] [Abstract][Full Text] [Related]
46. Implications of Heterogeneity of Epithelial-Mesenchymal States in Acromegaly Therapeutic Pharmacologic Response.
Gil J; Marques-Pamies M; Valassi E; García-Martínez A; Serra G; Hostalot C; Fajardo-Montañana C; Carrato C; Bernabeu I; Marazuela M; Rodríguez-Lloveras H; Cámara R; Salinas I; Lamas C; Biagetti B; Simó-Servat A; Webb SM; Picó A; Jordà M; Puig-Domingo M
Biomedicines; 2022 Feb; 10(2):. PubMed ID: 35203668
[TBL] [Abstract][Full Text] [Related]
47. Medical therapy of acromegaly: efficacy and safety of somatostatin analogues.
Feelders RA; Hofland LJ; van Aken MO; Neggers SJ; Lamberts SW; de Herder WW; van der Lely AJ
Drugs; 2009 Nov; 69(16):2207-26. PubMed ID: 19852525
[TBL] [Abstract][Full Text] [Related]
48. Maintenance of Acromegaly Control in Patients Switching From Injectable Somatostatin Receptor Ligands to Oral Octreotide.
Samson SL; Nachtigall LB; Fleseriu M; Gordon MB; Bolanowski M; Labadzhyan A; Ur E; Molitch M; Ludlam WH; Patou G; Haviv A; Biermasz N; Giustina A; Trainer PJ; Strasburger CJ; Kennedy L; Melmed S
J Clin Endocrinol Metab; 2020 Oct; 105(10):e3785-97. PubMed ID: 32882036
[TBL] [Abstract][Full Text] [Related]
49. Switching patients with acromegaly from octreotide to pasireotide improves biochemical control: crossover extension to a randomized, double-blind, Phase III study.
Bronstein MD; Fleseriu M; Neggers S; Colao A; Sheppard M; Gu F; Shen CC; Gadelha M; Farrall AJ; Hermosillo Reséndiz K; Ruffin M; Chen Y; Freda P;
BMC Endocr Disord; 2016 Apr; 16():16. PubMed ID: 27039081
[TBL] [Abstract][Full Text] [Related]
50. IGF-I Variability Over Repeated Measures in Patients With Acromegaly Under Long-Acting Somatostatin Receptor Ligands.
Maione L; Albrici C; Grunenwald S; Mouly C; Cimino V; Lecoq AL; Souberbielle JC; Caron P; Chanson P
J Clin Endocrinol Metab; 2022 Aug; 107(9):e3644-e3653. PubMed ID: 35772775
[TBL] [Abstract][Full Text] [Related]
51. Ki-67 is a predictor of acromegaly control with octreotide LAR independent of SSTR2 status and relates to cytokeratin pattern.
Kasuki L; Wildemberg LE; Neto LV; Marcondes J; Takiya CM; Gadelha MR
Eur J Endocrinol; 2013 Aug; 169(2):217-23. PubMed ID: 23749849
[TBL] [Abstract][Full Text] [Related]
52. Pharmacotherapy for acromegaly: future role for pasireotide?
Ben-Shlomo A
Endocrinol Metab Clin North Am; 2015 Mar; 44(1):35-41. PubMed ID: 25732640
[TBL] [Abstract][Full Text] [Related]
53. Impact of preoperative pasireotide therapy on invasive octreotide-resistant acromegaly.
Yamamoto R; Robert Shima K; Igawa H; Kaikoi Y; Sasagawa Y; Hayashi Y; Inoshita N; Fukuoka H; Takahashi Y; Takamura T
Endocr J; 2018 Oct; 65(10):1061-1067. PubMed ID: 30078825
[TBL] [Abstract][Full Text] [Related]
54. Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial.
Gadelha MR; Bronstein MD; Brue T; Coculescu M; Fleseriu M; Guitelman M; Pronin V; Raverot G; Shimon I; Lievre KK; Fleck J; Aout M; Pedroncelli AM; Colao A;
Lancet Diabetes Endocrinol; 2014 Nov; 2(11):875-84. PubMed ID: 25260838
[TBL] [Abstract][Full Text] [Related]
55. Long-term Efficacy and Safety of Pasireotide in Patients With Acromegaly: 14 Years of Single-Center Real-World Experience.
Gadelha M; Marques NV; Fialho C; Scaf C; Lamback E; Antunes X; Santos E; Magalhães J; Wildemberg LE
J Clin Endocrinol Metab; 2023 Nov; 108(12):e1571-e1579. PubMed ID: 37357993
[TBL] [Abstract][Full Text] [Related]
56. Effects of pegvisomant and somatostatin receptor ligands on incidence of vertebral fractures in patients with acromegaly.
Chiloiro S; Mazziotti G; Giampietro A; Bianchi A; Frara S; Mormando M; Pontecorvi A; Giustina A; De Marinis L
Pituitary; 2018 Jun; 21(3):302-308. PubMed ID: 29397538
[TBL] [Abstract][Full Text] [Related]
57. Truncated somatostatin receptor 5 may modulate therapy response to somatostatin analogues--Observations in two patients with acromegaly and severe headache.
Marina D; Burman P; Klose M; Casar-Borota O; Luque RM; Castaño JP; Feldt-Rasmussen U
Growth Horm IGF Res; 2015 Oct; 25(5):262-7. PubMed ID: 26188991
[TBL] [Abstract][Full Text] [Related]
58. Management of Hyperglycemia in Patients With Acromegaly Treated With Pasireotide LAR.
Samson SL
Drugs; 2016 Sep; 76(13):1235-1243. PubMed ID: 27473537
[TBL] [Abstract][Full Text] [Related]
59. Treatment escape reduces the effectiveness of cabergoline during long-term treatment of acromegaly in monotherapy or in association with first-generation somatostatin receptor ligands.
Kasuki L; Dalmolin MD; Wildemberg LE; Gadelha MR
Clin Endocrinol (Oxf); 2018 Jun; 88(6):889-895. PubMed ID: 29520805
[TBL] [Abstract][Full Text] [Related]
60. GH and IGF-I levels and tumor shrinkage in response to first generation somatostatin receptor ligands in acromegaly: a comparative study between two reference centers for pituitary diseases in Brazil.
Manosso KZB; Sampaio CL; Kasuki L; Antunes X; Gadelha MR; Boguszewski CL
Endocrine; 2021 Oct; 74(1):146-154. PubMed ID: 34041695
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
